The specimen validity testing market was valued at USD 1.04 Billion in 2017 and is expected to reach USD 1.49 Billion by 2023, growing at a CAGR of 6.3%. The base year considered for the study is 2017 and the forecast period is from 2018 to 2023.
The market is broadly segmented into products and services. The services segment is expected to register the highest growth rate during the forecast period. The high growth in this segment is attributed to the implementation of workplace drug testing in several countries, increase in the number of drug screening tests, and growing number of drug screening laboratories across the globe.
Based on product, the market is categorized into reagents, calibrators, & controls; assay kits; and disposables. In 2018, the reagents, calibrators, and controls segment is expected to account for the largest share of the market, owing to the repeated purchase of these products.
The market is dominated by North America, followed by Europe. The dominance of the North American market is attributed to factors such as the growing consumption of illicit drugs, the presence of stringent laws mandating drug screening, availability of government funding (to help curb drug abuse), and the presence of key players in the region.
While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests.
The market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher (US), Sciteck (US), American Bio Medica Corporation (ABMC), Alere (US), Express Diagnostics (US), and Premier Biotech. While, LabCorp (US), Quest Diagnostics (US), Alere Toxicology (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
Comments
Post a Comment